INS 018_073
Alternative Names: INS-018_073Latest Information Update: 01 Sep 2021
At a glance
- Originator InSilico Medicine
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Renal fibrosis
Most Recent Events
- 04 Aug 2021 Insilico Medicine plans to submit application for phase I trial in Renal fibrosis by the end of 2022 (Insilico Medicine website, August 2021)
- 04 Aug 2021 Pharmacodynamics and safety data from a preclinical trial in Renal fibrosis released by Insilico Medicine (Insilico Medicine website, August 2021)
- 04 Aug 2021 Insilico Medicine plans a phase I trial for Renal fibrosis (Insilico Medicine website, August 2021)